Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

Completed · Phase 2

Conditions studied: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or recurrent liver, bile duct, or gallbladder cancer.

Key facts

Study ID

NCT00003557

Run by

University of Chicago

People needed

16

Starts

1999-01-01

Expected to finish

2003-08-01

Last updated by the study team

2014-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Illinois at Chicago — Chicago, Illinois, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
• Cancer Care Specialists of Central Illinois, S.C. — Decatur, Illinois, United States
• Evanston Northwestern Health Care — Evanston, Illinois, United States
• Lutheran General Cancer Care Center — Park Ridge, Illinois, United States
• Illinois Oncology Research Association — Peoria, Illinois, United States
• Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
• Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
• Michiana Hematology/Oncology P.C. — South Bend, Indiana, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.